Volume 98, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



We evaluated the therapeutic efficacy of artemether–lumefantrine (AL) fixed-dose combination to treat uncomplicated malaria in Cruzeiro do Sul, Acre State, in the Amazon region of Brazil. Between December 2015 and May 2016, we enrolled 79 patients, 5–79 years old with fever or history of fever in the previous 48 hours and monoinfection confirmed by microscopy. Attempts were made to provide direct observation or phone reminders for all six doses of AL, and patients were followed-up for 28 days. AL was well tolerated, with no adverse events causing treatment interruption. All but one of the 74 patients who completed the 28-day follow-up had an adequate clinical and parasitologic response = 98.6% (95% CI: 93.2-100%). We could not amplify the one isolate of the case with recurrent infection to differentiate between recrudescence and reinfection. Five (6.3%) patients demonstrated persistent asexual parasitemia on Day 3, but none met definition for early treatment failure. We found no mutations in selected gene domains, known to be associated with artemisinin resistance in isolates from Day 0. These results strongly support the continued use of AL as a first-line therapy for uncomplicated malaria in Acre. Routine monitoring of in vivo drug efficacy coupled with molecular surveillance of drug resistance markers remains critical.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...


Data & Media loading...

  • Received : 04 Aug 2017
  • Accepted : 25 Sep 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error